Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) announced that it has filed a lawsuit for an injunction and damages (value of the subject matter of the suit is about 32 billion yen) against patent infringement, based on the patent on the anti-PD-L1 antibody owned by ONO (JP5885764; JP6258428), to the Tokyo District Court on February 28 against AstraZeneca K.K., which has been marketing Imfinzi® (durvalumab).

　ONO is a research and development company that creates world-class, innovative new drugs under the corporate philosophy, “Dedicated to the Fight against Disease and Pain.” We recognize intellectual property as an extremely important management asset. Therefore, we have decided to take appropriate measures against acts that infringe our intellectual property rights, leading to the filing of such a lawsuit this time.

　Considering that the treatment is related to the life-saving of patients, we will not ask for a sales injunction of Imfinzi® in this lawsuit, if we would make an agreement with AstraZeneca K.K. which will pay to ONO an appropriate consideration including royalties even outside the proceedings.